Recently diagnosed with HIV? Click here

Raltegravir

Displayed below is content from the NAPWA website tagged with the keyword raltegravir.

Once-daily raltegravir not as effective

Positive Living article • Adrian Ogier • 25 February 2011
Treating HIV

Merck has terminated a trial comparing once-daily dosing against the currently recommended twice-daily dosing of raltegravir. read more »

Raltegravir approved for first line

Positive Living article • Adrian Ogier • 3 September 2010
Treating HIV

The Pharmaceutical Benefits Scheme[Pharmaceutical Benefits Scheme] The federal government program which subsidises medication costs in Australia. Anti-HIV drugs are part of a special part of the PBS called Section 100 (S100) which is used for expensive, highly specialised drugs. (PBS) has broadened access to raltegravir (Isentress) beyond treatment-experienced adults.

Raltegravir is now also available for people who are first starting HIV treatment.

Raltegravir + Truvada is now one of four preferred commencing regimens in the Australian HIV Treatment Guidelines. read more »

News from IAS 2010

Positive Living article • Adrian Ogier • 2 September 2010

Adrian Ogier gives a round up of treatments news from the Vienna Conference. read more »

Syndicate content
Text size: font smallerfont normalfont larger

Stay in touch

NAPWHA's email newsletters provide regular info about issues affecting people with HIV and the response to HIV in Australia. Click here to subscribe.

Subscribe to Positive Living

Our free quarterly newsmagazine, Positive Living provides authoritative, independent information about living with HIV and HIV treatments. Click here to subscribe.

RSS feeds

Our website has RSS feeds covering all topic areas — just go to the topic area you're interested in and click the RSS feed icon.

Twitter users can stay up-to-date with NAPWHA's work and be alerted to new content on the website by following @napwa.

Join us on Facebook NAPWHA Facebook.

Find out more at LinkedIn

Find out more about NAPWHA at LinkedInNAPWHA at LinkedIn.

HIV Clinical Trials update